In November 2018, medical cannabis was legalized in the United Kingdom, meaning cannabis can be prescribed if no other licensed medicine could be of help to the patient. The policy of cannabis legalization for medical purposes is supported overwhelmingly by the British population. At the current moment, GPs are not able to prescribe cannabis to patients, only a specialist doctor can do this. Furthermore, the NHS will only advocate the use of medical cannabis in three circumstances: in cases of rare, severe epilepsy; to deal with chemotherapy effects such as nausea, or to help with multiple sclerosis.
The medical cannabis market in the UK is predicted to soar. At the end of 2019, there were less than 250 active medical cannabis users in the country; by 2024, this figure is expected to be over 337 thousand. The potential of the market in the UK is clear when the number of sufferers of medical conditions for whom medical cannabis is legal and available in other countries is taken into account. For example, there are 400 thousand sufferers of rheumatoid arthritis in the UK who could benefit from medical cannabis, and 360 thousand cancer cases a year for which medical cannabis could be available to combat the worst effects of chemotherapy. Furthermore, in 2028, the medical cannabis market in the UK is predicted to have a revenue of approximately 8.8 billion euros, which is forecast to be the second biggest in Europe, behind only France. The possible capacity of the medical cannabis market in the UK can be further seen in a survey that found over three-quarters of Brits would take medical cannabis if it was prescribed by a doctor.
This text provides general information. Statista assumes no
liability for the information given being complete or correct.
Due to varying update cycles, statistics can display more up-to-date
data than referenced in the text.
In the following 5 chapters, you will quickly find the 24 most important statistics relating to "Medical cannabis in the UK".